Renalytix plc

("Renalytix" or the "Company")

Notice of Interim Results and Investor Presentation

LONDON and NEW YORK, 12 March 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), which is commercialising kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment for chronic kidney disease, will announce its unaudited interim results for the six months ended 31 December 2024 on Tuesday 18 March 2025.

Investor Presentations

On-line investor presentation

Julian Baines, Executive Chairman, will be hosting a live interactive presentation on the Engage Investor platform, at 2:00pm (GMT) on 18 March 2025.

Renalytix welcomes all current shareholders and interested investors to join and encourages investors to pre-submit questions. Investors can also submit questions at any time during the live presentation.

Investors can sign up to Engage Investor at no cost and follow Renalytix plc from their personalised investor hub. Register interest in this event here: https://engageinvestor.news/RENX_IP25

A recording of the event will be available on the Engage Investor platform afterwards.

In-person investor presentation

Julian Baines will also provide an in-person presentation relating to the Company's interim results at 5.30pm GMT on Tuesday 25 March 2025, which is open to all existing and potential shareholders. The Company welcomes investors to 75 King William Street, London, EC4N 7BE from 5.15pm for a 5.30pm start and will be followed by refreshments.

If you would like to attend, please contact Walbrook PR on 020 7933 8780 or email renalytix@walbrookpr.com.

For further information, please contact:

About Renalytix (www.renalytix.com)

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for kidneyintelX.dkd which is now offered commercially in the United States.

Unrecognized and uncontrolled kidney disease remains one of the largest barriers to controlling cost and suffering in the United States and the United Kingdom's medical system, affecting over 14 million and 8 million people, respectively. After five years of development and clinical validation, kidneyintelX.dkd is the only FDA-approved and Medicare reimbursed prognostic tool capable of understanding a patient's risk with kidney disease early where treatment has maximal effect. kidneyintelX.dkd is now being deployed across large physician group practices and health systems in select regions of the United States.

The over 10,000 patients that have been tested by kidneyintelX.dkd have produced a substantial body of real-world performance data. In patient populations where kidneyintelX.dkd has been deployed, a demonstrated and significant increase in diagnosis, prognosis, and treatment rates have been recorded. kidneyintelX.dkd now has full reimbursement established by Medicare, the largest insurance payer in the United States, at $950 per reportable result. kidneyintelX.dkd is also recommended for use in the international chronic kidney disease clinical guidelines (KDIGO).